Michael Givertz, MD
Cardiovascular Disease · Brookline, MANPI 1265499560
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $121,702 of the $146,866 with a category attached, or 82.9%. 18 manufacturers reported payments, led by Merck at 47.5% of the total. Reporting peaked in 2019 at $47,754 and has fallen 59.8% since, to $19,195 in 2025. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 223 payments — averaging $658.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$70K
- Edwards Lifesciences$39K
- AstraZeneca$16K
- Acorda Therapeutics, Inc$10K
- Baxter Healthcare$4K
- Abbott$4K
- plus $4K from 12 others
Across 71 payments — averaging $6764.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$219K
- Actelion Pharmaceuticals, Ltd$148K
- Endotronix, Inc.$109K
- E.r. Squibb & Sons, L.L.C.$4K
- Novartis$804
What the payments were for
- Consulting fees$121,70283%
- Travel & lodging$17,43112%
- Food & beverage$7,7335%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 68 | $69,697 |
| Edwards Lifesciences | 49 | $39,000 |
| AstraZeneca | 26 | $15,864 |
| Acorda Therapeutics, Inc | 8 | $10,005 |
| Baxter Healthcare | 6 | $4,203 |
| Abbott | 33 | $3,905 |
| Bayer | 14 | $1,872 |
| Abiomed | 3 | $469 |
| Transmedics, Inc. | 1 | $439 |
| Cvrx, Inc. | 3 | $317 |
| Endotronix, Inc. | 1 | $294 |
| Medtronic(2 entities) | 2 | $270 |
| Biotronik Inc. | 2 | $140 |
| United Therapeutics Corporation | 1 | $103 |
| Pfizer | 1 | $86 |
| Amgen | 3 | $78 |
| Shockwave Medical, Inc | 1 | $64 |
| Teleflex LLC | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$9,037
- MK-1242$7,436
- FARXIGA$6,312
- Renal - PD$4,108
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,293
- VERQUVO$1,815
- Impella$469
- ORGAN CARE SYSTEM$439
- CARDIOMEMS$392
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$294
- HeartMate 3 Left Ventricular Dev$263
- HeartMate 3 Left Ventricular Assist Device$166
- Barostim Neo System$152
- Mitra Clip system$149
- Micra$143
- HeartWare HVAD$126
- HeartMate Touch$126
How this compares
$146,866 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 149 | $204,777 |
| JardianceEmpagliflozin | 96 | $120,029 |
| FarxigaDapagliflozin Propanediol | 90 | $115,594 |
| EliquisApixaban | 58 | $73,117 |
| XareltoRivaroxaban | 24 | $34,922 |
| Repatha SureclickEvolocumab | 16 | $10,579 |
| Rosuvastatin Calcium | 87 | $2,738 |
| Metoprolol Succinate | 123 | $2,723 |
| Ezetimibe | 22 | $1,940 |
| Dofetilide | 20 | $1,321 |
| Carvedilol | 88 | $1,215 |
| Atorvastatin Calcium | 60 | $1,149 |
| Amiodarone Hcl | 19 | $1,026 |
| Torsemide | 41 | $843 |
| Spironolactone | 79 | $818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $15,864 | $115,59490 claims |
| PfizerEliquis | $86 | $73,11758 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Other cardiovascular disease in Brookline
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- Kevin CroceChestnut Hill$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.